Summary: BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival. Cancer Discov; 7(6); 558–60. ©2017 AACR.
See related article by van Geel et al., p. 610.
from Cancer via ola Kala on Inoreader http://ift.tt/2ri2y1k
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου